npj Vaccines (Jul 2023)
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
- Kirsten E. Lyke,
- Robert L. Atmar,
- Clara Dominguez Islas,
- Christine M. Posavad,
- Meagan E. Deming,
- Angela R. Branche,
- Christine Johnston,
- Hana M. El Sahly,
- Srilatha Edupuganti,
- Mark J. Mulligan,
- Lisa A. Jackson,
- Richard E. Rupp,
- Christina A. Rostad,
- Rhea N. Coler,
- Martín Bäcker,
- Angelica C. Kottkamp,
- Tara M. Babu,
- David Dobrzynski,
- Judith M. Martin,
- Rebecca C. Brady,
- Robert W. Frenck,
- Kumaravel Rajakumar,
- Karen Kotloff,
- Nadine Rouphael,
- Daniel Szydlo,
- Rahul PaulChoudhury,
- Janet I. Archer,
- Sonja Crandon,
- Brian Ingersoll,
- Amanda Eaton,
- Elizabeth R. Brown,
- M. Juliana McElrath,
- Kathleen M. Neuzil,
- David S. Stephens,
- Diane J. Post,
- Bob C. Lin,
- Leonid Serebryannyy,
- John H. Beigel,
- David C. Montefiori,
- Paul C. Roberts,
- the DMID 21-0012 Study Group
Affiliations
- Kirsten E. Lyke
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine
- Robert L. Atmar
- Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine
- Clara Dominguez Islas
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Christine M. Posavad
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Meagan E. Deming
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine
- Angela R. Branche
- Department of Medicine, Division of Infectious Diseases, University of Rochester
- Christine Johnston
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Hana M. El Sahly
- Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine
- Srilatha Edupuganti
- Department of Medicine, Emory University School of Medicine
- Mark J. Mulligan
- NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine
- Lisa A. Jackson
- Kaiser Permanente Washington Health Research Institute
- Richard E. Rupp
- Sealy Institute for Vaccine Sciences, University of Texas Medical Branch
- Christina A. Rostad
- Department of Pediatrics and Center for Childhood Infections and Vaccines, Emory University School of Medicine and Children’s Healthcare of Atlanta
- Rhea N. Coler
- Seattle Children’s Research Institute, University of Washington School of Medicine
- Martín Bäcker
- NYU Langone Hospital—Long Island Vaccine Center Research Clinic and Division of Infectious Disease, Department of Medicine, NYU Long Island School of Medicine
- Angelica C. Kottkamp
- NYU Langone Vaccine Center and Division of Infectious Diseases and Immunology, Department of Medicine, NYU Grossman School of Medicine
- Tara M. Babu
- Department of Medicine, University of Washington
- David Dobrzynski
- Department of Medicine, Division of Infectious Diseases, University of Rochester
- Judith M. Martin
- Department of Pediatrics, University of Pittsburgh School of Medicine
- Rebecca C. Brady
- Cincinnati Children’s Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine
- Robert W. Frenck
- Cincinnati Children’s Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine
- Kumaravel Rajakumar
- Department of Pediatrics, University of Pittsburgh School of Medicine
- Karen Kotloff
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine
- Nadine Rouphael
- Department of Medicine, Emory University School of Medicine
- Daniel Szydlo
- Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center
- Rahul PaulChoudhury
- Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center
- Janet I. Archer
- FHI360
- Sonja Crandon
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Brian Ingersoll
- Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center
- Amanda Eaton
- Department of Surgery, Duke University Medical Center
- Elizabeth R. Brown
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- M. Juliana McElrath
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Kathleen M. Neuzil
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine
- David S. Stephens
- Department of Medicine, Emory University School of Medicine
- Diane J. Post
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Bob C. Lin
- Vaccine Immunology Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Leonid Serebryannyy
- Vaccine Immunology Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- John H. Beigel
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- David C. Montefiori
- Department of Surgery, Duke University Medical Center
- Paul C. Roberts
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- the DMID 21-0012 Study Group
- DOI
- https://doi.org/10.1038/s41541-023-00693-z
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 10
Abstract
Abstract As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.
